Zhifei’s CA111 Injection Approved for Clinical Trials Targeting Weight Loss and Hypoglycemia

Chongqing Zhifei Biological Co., Ltd’s (SHE: 300122) subsidiary, Chongqing Chenan Biopharmaceutical Co., Ltd., has received clinical trial approval from China’s National Medical Products Administration (NMPA) for CA111 Injection. The drug targets both weight loss and blood glucose control (hypoglycemia), directly competing in the market with Eli Lilly’s tirzepatide.

Drug Mechanism and Advantages
CA111 is a dual agonist targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual-target design offers synergistic mechanisms, providing superior efficacy in lowering blood sugar and reducing body weight while minimizing side effects. Currently, Eli Lilly’s tirzepatide Injection is the only approved GIP/GLP-1 dual agonist, with no domestic equivalents available in China.-Fineline Info & Tech